After many rocky years where it looked as though Immunocore might never realize its early promise, the UK biotech company is back on track, and expected to complete a $100m IPO within days.
The Oxford-headquartered firm was spun out from Medigene in 2008 with a focus on developing a new kind of immunotherapy,...






